Pulmonary Alveolar Proteinosis Overview

Principles

Definition

Pulmonary alveolar proteinosis is a research concept focused on a rare respiratory disorder characterized by the abnormal accumulation of surfactant components within the alveolar spaces of the lungs. This academic domain investigates the complex interplay of factors involved in surfactant metabolism and clearance, particularly the critical role of alveolar macrophages and the GM-CSF signaling pathway, thereby offering significant insights into lung homeostasis and potential therapeutic strategies for related pulmonary conditions.

Ontological type

Pathophysiology

Therapeutic Strategies

Etiology and Classification

Key developments

Key Figures

Macrophage Paradigm Consolidation era

J Ferin [1] was a key figure in the Macrophage Paradigm Consolidation era (1960-1993) with associations including the University of Rochester [2]. His key contributions in this era are exemplified by the 1992 paper 'Role of the alveolar macrophage in lung injury: studies with ultrafine particles' [3], which highlighted the alveolar macrophage's role in lung injury and particle handling. In this context, Ferin [1] advanced the macrophage-centered framework by emphasizing macrophage processing of surfactant and their role in alveolar clearance, ideas that underpinned later clinical approaches. The 1992 study's findings illuminated enzymatic and mediator pathways linking macrophage dysfunction to surfactant accumulation, shaping the era's emphasis on macrophage regulation and lavage-based clearance [3].

GM-CSF Autoimmune Era era

Harold A. Chapman [1] was associated with Harvard University [3] and the Massachusetts Institute of Technology [4] during the GM-CSF Autoimmune Era (1994-2007). His key contributions in this era come from the 2006 paper Alveolar epithelial cell mesenchymal transition develops <i>in vivo</i> during pulmonary fibrosis and is regulated by the extracellular matrix [7], which revealed ECM-regulated lung remodeling processes that interact with alveolar clearance mechanisms central to GM-CSF–driven macrophage maturation and surfactant handling. Dean Sheppard [2] is affiliated with the University of California, San Francisco [5] and the University of Pennsylvania [6] during this era. His key contribution in this era, based on the same 2006 paper Alveolar epithelial cell mesenchymal transition develops <i>in vivo</i> during pulmonary fibrosis and is regulated by the extracellular matrix [7], highlighted ECM regulation of alveolar epithelial–mesenchymal transition and its implications for alveolar remodeling and surfactant clearance, informing the GM-CSF autoimmune impairment of macrophage maturation.

Integrated Surfactant Homeostasis era

Scott H. Randell [1] is associated with Indiana University School of Medicine [3] and the University of Utah [4] during the Integrated Surfactant Homeostasis era. In this era his key contribution, evidenced by the 2013 paper Type 2 alveolar cells are stem cells in adult lung [7], is the identification of Type 2 alveolar cells as resident stem cells that can drive epithelial renewal, a finding that reframes surfactant homeostasis and alveolar repair. Barry R. Stripp [2] is associated with University of Pittsburgh [5] and Duke University [6] in this era. His contribution centers on the same 2013 paper [7], emphasizing Type 2 alveolar cells as stem cells and their role in alveolar lipid handling and coordination with macrophage lipid turnover, a mechanistic insight with therapeutic implications.